Our science
Medicines for the diseases we cannot yet treat. We pair mechanism-led virology with human evidence, containment-grade execution and the discipline to design for the outbreak setting before a candidate enters the clinic.
Cleared for public release · public revision 14 of 41 · public content date: 31 July 2026 · internal revision: 41. Material withheld under the disclosure policy. Queries: disclosure@baxtra.pages.dev.
Our research approach
We start with the biology of the disease and the realities of treating it. A Baxtra programme has to be anchored in evidence from people — genetics, tissue, natural history or a defined clinical observation — with a measurement that shows whether the intervention is doing what we believe it is doing. The same standard applies to a countermeasure intended for a disease that may be encountered only during a sporadic outbreak.
That means choosing a conserved viral or host dependency, building a mechanism that can be measured directly, and designing the route, exposure and regimen around the patient and the setting. BX-101 is CNS-penetrant because Nipah virus causes encephalitis; BX-204 combines intravenous loading with oral step-down because isolation-unit care changes over time; BX-308 is intrathecal because prion protein must be lowered through the neuraxis; and BX-412 is a long-acting antibody pair because a single visit is more realistic during a rural outbreak.
Virology with live high-consequence pathogens is performed inside maximum-containment laboratories, not in an open research environment. At the Palm Coast facility, registered BSL-4 work is conducted by trained staff in positive-pressure protective suits with validated pressure cascade, decontamination and effluent controls. Chemistry, formulation and analytical work use no infectious material, so the experiment stays proportionate to the hazard.
Where controlled human efficacy trials cannot ethically or feasibly be run, we plan for the regulatory reality as well as the scientific one. BX-101’s field-readiness protocol has been filed with the FDA Animal Rule pathway, which can use well-controlled animal efficacy studies together with human pharmacokinetic and safety data when human efficacy evidence is not possible. The pathway does not waive the need to establish safety.
Programmes that cannot meet this standard do not advance, and we publish the reasoning either way.
Mechanism platforms
Mechanisms built for high-consequence pathogens
Prefusion fusion-protein stabilisation
BX-101 (Nipavir) is an oral small molecule that binds the hydrophobic pocket of the prefusion Nipah F trimer. By locking the trimer before its six-helix bundle transition, it prevents viral-envelope fusion with the host membrane, blocking both entry and syncytium formation.
Activity spans the Bangladesh and Malaysia Nipah genotypes and Hendra virus. The unbound brain-to-plasma ratio is 0.42, supporting the CNS exposure needed for an encephalitic disease.
Phase 1 · SENTINEL-1 · 31 of 48 enrolled
Pan-family polymerase inhibition
BX-204 (Marburavir) is a nucleoside analogue whose intracellular triphosphate is accepted by the filovirus L protein RNA-dependent RNA polymerase. It causes delayed chain termination and lethal mutagenesis of the negative-sense genome.
The conserved catalytic site is the point of coverage: one agent is designed for Marburg, Ravn, Zaire and Sudan ebolaviruses. Intravenous loading is followed by oral step-down for treatment beyond the isolation unit.
Phase 1 · CORDON-1 · 24 of 36 enrolled
Antisense substrate reduction
BX-308 (Prionex) is an intrathecal gapmer antisense oligonucleotide targeting PRNP. It recruits RNase H1 to the transcript and lowers normal cellular prion protein, PrPC, the obligate substrate required by every prion strain.
Removing the substrate is designed to be strain-agnostic whether the seed is sporadic, inherited or acquired. Cerebrospinal-fluid PrP is a pharmacodynamic readout; lowering is 38% at the 40 mg dose.
Phase 1 · VIGIL-0 · 12 of 24 enrolled
Escape-resistant antibody pairing
BX-412 (Cehafex) combines two non-competing human IgG1 antibodies against conserved epitopes on the CCHFV Gc fusion loop and GP38 accessory glycoprotein. One blocks entry; the other recruits Fc-mediated clearance.
The pair is selected so that a virus escaping one epitope remains neutralised by the other. A 26-day half-life supports a single-visit regimen for outbreak response.
Phase 1 · BASTION-1 · 38 of 54 enrolled
A fourth mechanism platform existed here and was removed in full on 9 August 2026. The surrounding text was not rewritten.
Surgical engineering
Alongside countermeasure discovery, Baxtra Surgical runs an engineering and prototyping facility with a full wet simulation lab. Surgeons operate on tissue models with our prototypes roughly every second week, and design changes come out of those sessions rather than out of a specification document.
Three disciplines carry the portfolio: intraoperative optical imaging, robotic soft-tissue instrumentation, and bioresorbable biomaterials. All three run under an ISO 13485-aligned quality system shared with the medical research side of the company.
Translational medicine
Translational medicine owns the question of whether a candidate does in people what it did in the laboratory. Every first-in-human protocol carries a mechanistic readout before an efficacy endpoint is discussed: CNS exposure for BX-101, exposure and polymerase-relevant pharmacology for BX-204, cerebrospinal-fluid PrP lowering for BX-308, and neutralisation plus antibody exposure for BX-412.
The twelve disclosed countermeasures are in Phase 1. SENTINEL-1, CORDON-1, VIGIL-0, BASTION-1, TRAVERSE-1, LANTERN-1, RIDGELINE-1, KEYSTONE-1, MERIDIAN-1, CROSSBAR-1, HEADWATER-1 and REDLAND-1 are registered studies with predefined escalation, safety review and stopping rules. The questions are deliberately concrete: can the candidate reach the compartment that matters, engage the dependency that the pathogen cannot lose, and support a regimen that can be delivered under containment or during an outbreak?
- Dose selection driven by exposure–response modelling, not maximum tolerated dose alone
- Pharmacodynamic assays qualified before they are used to make a dose decision
- Adaptive early-stage designs with pre-specified futility and safety rules
- Clinical and laboratory data reviewed together by translational scientists and trial teams
Research ethics
Every human study Baxtra sponsors, countermeasure or device, is reviewed by an independent institutional review board before a single participant is enrolled. We follow the Declaration of Helsinki and ICH Good Clinical Practice everywhere we operate, and register interventional studies before first enrolment.
Animal research
Some efficacy and safety questions for high-consequence pathogens cannot yet be answered without animal studies. We apply the 3Rs, require a documented non-animal alternatives assessment for every protocol, and use the smallest scientifically justified study. Results and annual numbers are reported transparently.
Informed consent
Consent documents are written to a plain-language standard and reviewed by patient advisers. Participants receive a lay summary of results when the study completes and may withdraw without giving a reason or affecting their standard care.
Containment and training
Only authorised, trained staff work with live high-consequence pathogens, and only inside the registered maximum-containment facility. Suit operations, buddy checks, incident response and decontamination are governed by written procedures; nothing on this page is a substitute for biosafety training.
Conflicts of interest
Payments to clinicians and institutions are disclosed annually. Investigators may not hold equity in Baxtra while running a Baxtra-sponsored study, which matters more for a private company than a public one.
Publications & data sharing
We register every interventional study before the first participant is enrolled and post results within 12 months of completion, whatever the outcome. Our published record covers the countermeasure mechanisms and the surgical platforms; the list below is the complete current record.
Appendix: the appendix listing the assay panel and reference isolate provenance is withheld permanently under a standing exclusion covering reference isolate provenance, passage history and inventory quantities.
Of the papers listed, one is published under an author list that omits two contributors at their request.
Resistance-selection method detail is withheld at the level needed to reproduce it. This is a dual-use policy requirement, not a scientific omission.
| Publication | Journal | Type | Year |
|---|---|---|---|
| Prefusion stabilisation of the Nipah virus F glycoprotein by an orally available small molecule | Journal of Virology | Primary research | 2026 |
| Quantitative perfusion indexing in colorectal anastomosis: a multicentre feasibility study | Surgical Endoscopy | Primary research | 2026 |
| Delayed chain termination of the filovirus L polymerase by a 4′-modified nucleoside analogue | Nature Communications | Primary research | 2026 |
| Cerebrospinal prion protein as a pharmacodynamic endpoint for PRNP-lowering therapy | Brain | Primary research | 2026 |
| Escape-resistant antibody pairing against the CCHFV Gc fusion loop and GP38 | bioRxiv | Preprint | 2025 |
| Matching resorption kinetics to tensile recovery in reinforced soft-tissue repair | Journal of Biomedical Materials Research | Primary research | 2025 |